ASX:NSB +61 8 6268 2641 ir@neuroscientific.com Level 4, 216 St Georges Terrace, PERTH, WA, AUSTRALIA, 6000 ASX Announcement 13 October 2026 US FDA Provides Positive Feedback on Planned Phase 2 Crohn's Disease Trial FDA supports proposed trial design, existing human data package and StemSmart™...